← Leaderboards
Qizhi C. Yao
Michael E Debakey Va Medical Center
$4,899,742
Attributed
$4,899,742
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $488.5K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,899,742 · 6
VA$0 · 4
By mechanism
R01$3,530,838 · 2
R21$1,192,379 · 3
R56$176,525 · 1
I01$0 · 3
IK6$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasTumorMouse ModelResponseVirus-Like ParticleMesothelinEffective TherapyVaccinesCellsTreatment EfficacyInnovationBaseResearch PersonnelGeneral PopulationVeteransImmuneCytokineSamplingIn VitroPancreatic Ductal AdenocarcinomaPre-ClinicalAnimal ModelTumor ProgressionVaccination
Grant awards (29)
BLR&D Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Novel Pathogenic Roles and Mechanisms of Fibrinogen in Pancreatic Cancer$0
I01 · FY2025 · VA · contact PI
Stratification of Pancreatic Cancer Subpopulations for Effective Immunotherapy$0
I01 · FY2024 · VA · contact PI
Novel Pathogenic Roles and Mechanisms of Fibrinogen in Pancreatic Cancer$0
I01 · FY2024 · VA · contact PI
Stratification of Pancreatic Cancer Subpopulations for Effective Immunotherapy$0
I01 · FY2023 · VA · contact PI
Stratification of Pancreatic Cancer Subpopulations for Effective Immunotherapy$0
I01 · FY2022 · VA · contact PI
Stratification of Pancreatic Cancer Subpopulations for Effective Immunotherapy$0
I01 · FY2021 · VA · contact PI
Stratification of Pancreatic Cancer Subpopulations for Effective Immunotherapy$0
I01 · FY2020 · VA · contact PI
A novel miR-198 replacement therapy for pancreatic cancer$459,697
R01 · FY2019 · CA · contact PI
A novel miR-198 replacement therapy for pancreatic cancer$473,915
R01 · FY2018 · CA · contact PI
A novel miR-198 replacement therapy for pancreatic cancer$473,915
R01 · FY2017 · CA · contact PI
A novel miR-198 replacement therapy for pancreatic cancer$473,915
R01 · FY2016 · CA · contact PI
A novel miR-198 replacement therapy for pancreatic cancer$472,669
R01 · FY2015 · CA · contact PI
Chimeric SHIV VLP as an oral mucosal HIV vaccine$0
I01 · FY2015 · VA · contact PI
Chimeric SHIV VLP as an oral mucosal HIV vaccine$0
I01 · FY2014 · VA · contact PI
Chimeric SHIV VLP as an oral mucosal HIV vaccine$0
I01 · FY2013 · VA · contact PI
Chimeric SHIV VLP as an oral mucosal HIV vaccine$0
I01 · FY2012 · VA · contact PI
Enhancement of dendritic cell vaccine efficiency against pancreatic cancer by M--$202,620
R21 · FY2010 · CA · contact PI
Oral mucosal SHIV VLP vaccination against HIV$176,525
R56 · FY2010 · DE · contact PI
Enhancement of dendritic cell vaccine efficiency against pancreatic cancer by MSK$168,850
R21 · FY2009 · CA · contact PI
Influenza HA in SHIV VLPS for mucosal vaccination$293,927
R01 · FY2006 · DE · contact PI
Ginkgo Biloba Enhances Therapeutic HIV Vaccination$183,093
R21 · FY2006 · AT · contact PI
Influenza HA in SHIV VLPS for mucosal vaccination$301,000
R01 · FY2005 · DE
Ginkgo Biloba Enhances Therapeutic HIV Vaccination$187,500
R21 · FY2005 · AT
Influenza HA in SHIV VLPS for mucosal vaccination$290,900
R01 · FY2004 · DE
Influenza HA in SHIV VLPS for mucosal vaccination$290,900
R01 · FY2003 · DE
ENHANCEMENT OF HIV IMMUNOGENICITY BY INFLUENZA VIRUS$225,750
R21 · FY2002 · AI
ENHANCEMENT OF HIV IMMUNOGENICITY BY INFLUENZA VIRUS$117,461
R21 · FY2001 · AI
ENHANCEMENT OF HIV IMMUNOGENICITY BY INFLUENZA VIRUS$107,105
R21 · FY2001 · AI